Paradigm Biopharmaceuticals Ltd has released a press release.
Appendix 4E and 2018 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- PAR achieves 60 per cent reduction in osteoarthritis pain
- PAR achieves 100 per cent recruitment in Phase 2b OA Trial
- PAR - 50% reduction in osteoarthritis pain maintained
- Paradigm OA Phase 2b Clinical Trial over 80% Recruited
- Paradigms phase 2 clinical data update
Later from Paradigm Biopharmaceuticals
- Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
- PAR reports pain reduction in oa patients
- Paradigm Raises A$9 Million
- Paradigms Updated Corporate Presentation
- Paradigm Agreement With USA Past Players Network
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals